 Connection
Nikita Pozdeyev to Humans
This is a "connection" page, showing publications Nikita Pozdeyev has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.337 |
|
|
|
-
Goens C, Apey C, San Martín T, Bustíos N, Lira MJ, Pozdeyev N. Clinical validation of an artificial intelligence model for thyroid fine-needle aspiration biopsy indication: comparison with TI-RADS systems and human specialists in a Chilean public hospital. Front Endocrinol (Lausanne). 2026; 17:1809473.
Score: 0.024
-
White SL, Brasher MS, Pattee J, Zhou W, Chapman S, Jee YH, Bell CC, Jamil TL, Barrio M, Arehart CH, Evans LM, Hirbo J, Cox NJ, Straub P, Namba S, Bertucci-Richter E, Guare L, Edris A, Morris S, Mulford AJ, Zhang H, Fennessy B, Tobin MD, Chen J, Williams AT, John C, van Heel DA, Mathur R, Finer S, Moksnes MR, Brumpton BM, Åsvold BO, Peculis R, Rovite V, Konrade I, Wang Y, Crooks K, Chavan S, Fisher MJ, Rafaels N, Lin M, Shortt JA, Sanders AR, Whiteman DC, MacGregor S, Medland SE, Thorsteinsdóttir U, Stefánsson K, Karaderi T, Egan KM, Bocklage T, McCrary HC, Riedlinger G, Salhia B, Shriver C, Phan MD, Farlow JL, Edge S, Kaur V, Churchman ML, Rounbehler RJ, Brock PL, Ringel MD, Pividori M, Schweppe R, Raeburn CD, Walters RG, Chen Z, Li L, Matsuda K, Okada Y, Zöllner S, Verma A, Preuss MH, Kenny E, Hendricks AE, Fishbein L, Kraft P, Daly MJ, Neale BM, Martin AR, Cole JB, Haugen BR, Gignoux CR, Pozdeyev N. Global multi-ancestry genome-wide analyses identify genes and biological pathways associated with thyroid cancer and benign thyroid diseases. Nat Genet. 2026 Feb; 58(2):307-316.
Score: 0.023
-
Pozdeyev N, White SL, Bell CC, Haugen BR, Thomas J. Artificial Intelligence Applications in Thyroid Cancer Care. J Clin Endocrinol Metab. 2026 01 21; 111(2):316-324.
Score: 0.023
-
White SL, Jamil T, Bell C, Fishbein L, Haugen BR, Gignoux CR, Pozdeyev N. Population Prevalence of the Major Thyroid Cancer-Associated Syndromes. J Clin Endocrinol Metab. 2025 Nov 18; 110(12):e4049-e4054.
Score: 0.023
-
Bell C, White SL, Tylee T, Dighe M, Greca A, Goldner W, Mayson S, Haugen BR, Pozdeyev N. Thyroid Nodule Sphericity Metrics Discriminate Benign and Malignant Follicular and Oncocytic Neoplasms. Thyroid. 2025 03; 35(3):291-297.
Score: 0.022
-
Pozdeyev N, Dighe M, Barrio M, Raeburn C, Smith H, Fisher M, Chavan S, Rafaels N, Shortt JA, Lin M, Leu MG, Clark T, Marshall C, Haugen BR, Subramanian D, Crooks K, Gignoux C, Cohen T. Thyroid Cancer Polygenic Risk Score Improves Classification of Thyroid Nodules as Benign or Malignant. J Clin Endocrinol Metab. 2024 01 18; 109(2):402-412.
Score: 0.020
-
Barrio M, Raeburn CD, McIntyre R, Albuja-Cruz M, Haugen BR, Pozdeyev N. Computer-Assisted Levothyroxine Dose Selection for the Treatment of Postoperative Hypothyroidism. Thyroid. 2023 05; 33(5):547-555.
Score: 0.019
-
Pozdeyev N, Fishbein L, Gay LM, Sokol ES, Hartmaier R, Ross JS, Darabi S, Demeure MJ, Kar A, Foust LJ, Koc K, Bowles DW, Leong S, Wierman ME, Kiseljak-Vassiliades K. Targeted genomic analysis of 364 adrenocortical carcinomas. Endocr Relat Cancer. 2021 08 16; 28(10):671-681.
Score: 0.017
-
Pozdeyev N, Erickson TA, Zhang L, Ellison K, Rivard CJ, Sams S, Hirsch FR, Haugen BR, French JD. Comprehensive Immune Profiling of Medullary Thyroid Cancer. Thyroid. 2020 09; 30(9):1263-1279.
Score: 0.016
-
Pozdeyev N, Rose MM, Bowles DW, Schweppe RE. Molecular therapeutics for anaplastic thyroid cancer. Semin Cancer Biol. 2020 04; 61:23-29.
Score: 0.015
-
Pozdeyev N, Patel A, Pottinger PS, Leu M, Payne TH. Adherence to Recommended Post-Splenectomy Immunizations to Reduce the Risk of Sepsis: The University of Washington Experience. Am J Med Qual. 2020 Sep/Oct; 35(5):405-410.
Score: 0.015
-
Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res. 2018 07 01; 24(13):3059-3068.
Score: 0.013
-
Pozdeyev N, Yoo M, Mackie R, Schweppe RE, Tan AC, Haugen BR. Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies. Oncotarget. 2016 Aug 09; 7(32):51619-51625.
Score: 0.012
-
Pozdeyev N, Berlinberg A, Zhou Q, Wuensch K, Shibata H, Wood WM, Haugen BR. Targeting the NF-?B Pathway as a Combination Therapy for Advanced Thyroid Cancer. PLoS One. 2015; 10(8):e0134901.
Score: 0.011
-
Kar A, Banerjee T, Pozdeyev N, Holmstoen TB, Foust LJ, Bagby SM, Pitts TM, Habra MA, Wierman ME, Kiseljak-Vassiliades K. Comprehensive profiling of OTSSP167 action in adrenocortical carcinoma. Endocrinology. 2026 Sep 03; 167(10).
Score: 0.006
-
Jee YH, Pozdeyev N, Gignoux CR, White S, Haugen BR, Verma A, Peculis R, Rovite V, Mulford AJ, Sanders AR, Kitahara CM, Reeve MP, Kraft P, Martin AR. Genetic drivers of etiologic heterogeneity in thyroid cancer. Nat Commun. 2026 Jul 10; 17(1).
Score: 0.006
-
Guo B, Cai Y, Kim D, Smit RAJ, Wang Z, Iyer KR, Hilliard AT, Haessler J, Tao R, Broadaway KA, Wang Y, Pozdeyev N, Stæger FF, Yang C, Vanderwerff B, Patki AD, Stalbow L, Lin M, Rafaels N, Shortt J, Wiley L, Stanislawski M, Pattee J, Davis L, Straub PS, Shuey MM, Cox NJ, Lee NR, Jørgensen ME, Bjerregaard P, Larsen C, Hansen T, Moltke I, Meigs JB, Stram DO, Yin X, Zhou X, Chang KM, Clarke SL, Guarischi-Sousa R, Lankester J, Tsao PS, Buyske S, Graff M, Raffield LM, Sun Q, Wilkens LR, Carlson CS, Easton CB, Liu S, Manson JE, Marchand LL, Haiman CA, Mohlke KL, Gordon-Larsen P, Albrechtsen A, Boehnke M, Rich SS, Manichaikul A, Rotter JI, Yousri NA, Irvin RM, Gignoux C, North KE, Loos RJF, Assimes TL, Peters U, Kooperberg C, Raghavan S, Highland HM, Darst BF. Polygenic risk score for type 2 diabetes shows context-dependent effects across populations. Nat Commun. 2025 Oct 01; 16(1):8632.
Score: 0.006
-
Stoneman HR, Price AM, Trout NS, Lamont R, Tifour S, Pozdeyev N, Crooks K, Lin M, Rafaels N, Gignoux CR, Marker KM, Hendricks AE. Characterizing substructure via mixture modeling in large-scale genetic summary statistics. Am J Hum Genet. 2025 02 06; 112(2):235-253.
Score: 0.005
-
Barrio MJ, Pozdeyev N, McIntyre RC, Albuja-Cruz MB, Haugen BR, Raeburn CD. Long term outcomes after repeat lymph node dissections for persistent or recurrent differentiated thyroid cancer. Am J Surg. 2025 Jan; 239:116045.
Score: 0.005
-
Barrio MJ, Pozdeyev N, Raeburn CD, McIntyre RC, Marshall CB, Haugen B, La Greca A. Pre-operative thyroglobulin measurement for thyroid cancer risk of recurrence and response to therapy. Am J Surg. 2024 Dec; 238:115818.
Score: 0.005
-
Wiley LK, Shortt JA, Roberts ER, Lowery J, Kudron E, Lin M, Mayer D, Wilson M, Brunetti TM, Chavan S, Phang TL, Pozdeyev N, Lesny J, Wicks SJ, Moore ET, Morgenstern JL, Roff AN, Shalowitz EL, Stewart A, Williams C, Edelmann MN, Hull M, Patton JT, Axell L, Ku L, Lee YM, Jirikowic J, Tanaka A, Todd E, White S, Peterson B, Hearst E, Zane R, Greene CS, Mathias R, Coors M, Taylor M, Ghosh D, Kahn MG, Brooks IM, Aquilante CL, Kao D, Rafaels N, Crooks KR, Hess S, Barnes KC, Gignoux CR. Building a vertically integrated genomic learning health system: The biobank at the Colorado Center for Personalized Medicine. Am J Hum Genet. 2024 01 04; 111(1):11-23.
Score: 0.005
-
Hicks HM, Pozdeyev N, Sams SB, Pugazhenthi U, Bales ES, Hofmann MC, McKenna LR, Schweppe RE. Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2. Mol Cancer Res. 2023 09 01; 21(9):867-880.
Score: 0.005
-
Alzofon N, Koc K, Panwell K, Pozdeyev N, Marshall CB, Albuja-Cruz M, Raeburn CD, Nathanson KL, Cohen DL, Wierman ME, Kiseljak-Vassiliades K, Fishbein L. Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression. Mol Cancer Res. 2021 09; 19(9):1476-1485.
Score: 0.004
-
Hicks HM, McKenna LR, Espinoza VL, Pozdeyev N, Pike LA, Sams SB, LaBarbera D, Reigan P, Raeburn CD, E Schweppe R. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Mol Carcinog. 2021 03; 60(3):201-212.
Score: 0.004
-
Landa I, Pozdeyev N, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Genetics of Human Thyroid Cancer Cell Lines-Response. Clin Cancer Res. 2019 11 15; 25(22):6883-6884.
Score: 0.004
-
Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. Clin Cancer Res. 2019 05 15; 25(10):3141-3151.
Score: 0.004
-
Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Mol Cancer Res. 2019 05; 17(5):1036-1048.
Score: 0.004
-
Kessler BE, Mishall KM, Kellett MD, Clark EG, Pugazhenthi U, Pozdeyev N, Kim J, Tan AC, Schweppe RE. Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. Oncogene. 2019 04; 38(14):2565-2579.
Score: 0.004
-
Oweida A, Phan A, Vancourt B, Robin T, Hararah MK, Bhatia S, Milner D, Lennon S, Pike L, Raben D, Haugen B, Pozdeyev N, Schweppe R, Karam SD. Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. Thyroid. 2018 06; 28(6):739-747.
Score: 0.003
-
Kiseljak-Vassiliades K, Zhang Y, Bagby SM, Kar A, Pozdeyev N, Xu M, Gowan K, Sharma V, Raeburn CD, Albuja-Cruz M, Jones KL, Fishbein L, Schweppe RE, Somerset H, Pitts TM, Leong S, Wierman ME. Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer. 2018 04; 25(4):437-451.
Score: 0.003
-
Albuja-Cruz MB, Pozdeyev N, Robbins S, Chandramouli R, Raeburn CD, Klopper J, Haugen BR, McIntyre R. A "safe and effective" protocol for management of post-thyroidectomy hypocalcemia. Am J Surg. 2015 Dec; 210(6):1162-8; discussion 1168-9.
Score: 0.003
-
Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, Agarwal R, Pozdeyev N, Wood WM, Haugen BR. Nuclear factor ?B-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab. 2014 Aug; 99(8):E1436-44.
Score: 0.003
-
Peachey NS, Ray TA, Florijn R, Rowe LB, Sjoerdsma T, Contreras-Alcantara S, Baba K, Tosini G, Pozdeyev N, Iuvone PM, Bojang P, Pearring JN, Simonsz HJ, van Genderen M, Birch DG, Traboulsi EI, Dorfman A, Lopez I, Ren H, Goldberg AF, Nishina PM, Lachapelle P, McCall MA, Koenekoop RK, Bergen AA, Kamermans M, Gregg RG. GPR179 is required for depolarizing bipolar cell function and is mutated in autosomal-recessive complete congenital stationary night blindness. Am J Hum Genet. 2012 Feb 10; 90(2):331-9.
Score: 0.002
-
Tosini G, Pozdeyev N, Sakamoto K, Iuvone PM. The circadian clock system in the mammalian retina. Bioessays. 2008 Jul; 30(7):624-33.
Score: 0.002
-
Iuvone PM, Tosini G, Pozdeyev N, Haque R, Klein DC, Chaurasia SS. Circadian clocks, clock networks, arylalkylamine N-acetyltransferase, and melatonin in the retina. Prog Retin Eye Res. 2005 Jul; 24(4):433-56.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|